News

A new analysis of 11 global studies shows that people tend to regain lost weight after stopping anti-obesity medications like ...
British mother Lucy took to her TikTok @lucy52915 to showcase her impressive weight loss journey - and share her three top ...
There's been plenty of buzz about this class of drug, following publication of a high-profile trial this year. How much do we ...
Significantly lower risks seen for those receiving GLP-1 receptor agonists compared with other antidiabetic drugs.
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...
CBL-514, Caliway's first-in-class lipolysis drug candidate, has been granted clearance from the U.S. FDA to proceed with SUPREME-01, a global, ...
FAT jabs do often sound like a magical quick fix to overeating and demanding hunger pangs.  But the drugs can leave some ...
A MUM who lost a staggering nine stone on a weight-loss jab says her hair started falling out in clumps, until she found an ...
Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...
Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...